Lanreotide Powder Cas No.108736-35-2
Source: Synthetic
Specification: ≥99%
CAS No: 108736-35-2
Molecular Formula: C₅₄H₆₉N₁₁O₁₀S₂
Molecular Weight: 1096.3 g/mol
Analytical Method: HPLC
Active Ingredient: Lanreotide
Product Characteristics: White or off-white lyophilized powder or solid
Packaging: Available in various specifications (mg, g, kg), customizable
Storage Condition: Should be sealed, protected from light, and stored in a dry environment at -20°C or lower
Shelf Life: 24 months
Declaration of Use: This product is intended for industrial use or scientific research only.
Lanreotide API | CAS 108736-35-2 | Somatostatin Analog
Lanreotide is a highly potent, synthetic octapeptide analog of naturally occurring somatostatin. Engineered for advanced biopharmaceutical research, Xi'an Tihealth Biotechnology Co., Ltd. supplies this active pharmaceutical ingredient (API) with a rigorously validated HPLC purity of ≥ 99.0%. Characterized by its extended in vivo half-life and exceptionally high binding affinity to somatostatin receptors (specifically SSTR2 and SSTR5), our Lanreotide API is structurally optimized for the development of advanced sustained-release (SR) depot formulations and targeted neuroendocrine therapeutics.
⚠️ REGULATORY COMPLIANCE & RESEARCH USE ONLY (RUO)
Industrial R&D Application: This high-purity Lanreotide is supplied strictly as a raw material API powder for professional laboratory research, biopharmaceutical formulation development, and in-vitro/in-vivo assays. It is NOT a finished pharmaceutical drug and is explicitly prohibited for direct administration to humans or animals.
Chemical Profile & Specification Parameters
| Analytical Parameter | Xi'an Tihealth Specification |
|---|---|
| Generic Name | Lanreotide (Acetate) |
| CAS Number | 108736-35-2 |
| Molecular Formula | C54H69N11O10S2 |
| Molecular Weight | 1096.3 g/mol |
| Peptide Purity (HPLC) | ≥ 99.0% |
| Appearance | White to off-white lyophilized powder |
Storage & Handling Protocols: Preserve in tight, light-resistant containers. Store strictly at -20°C in a desiccated environment to maintain the disulfide bridge structural integrity. Allow the sealed vial to equilibrate to room temperature before opening to prevent hygroscopic degradation.
Pharmacodynamics & Receptor Interaction
Lanreotide exerts its broad-spectrum inhibitory effects by acting as a highly selective agonist at somatostatin receptors (SSTRs) located on the membranes of various endocrine and exocrine cells. The molecular mechanism initiates a profound intracellular signal transduction cascade:
- Hormonal Secretion Suppression: High-affinity binding to SSTR2 and SSTR5 closes cellular calcium channels and modulates potassium efflux, potently suppressing the pathological hypersecretion of Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), glucagon, and gastrointestinal peptides (gastrin, VIP, secretin).
- Antiproliferative Cascade: Receptor activation upregulates protein tyrosine phosphatases (PTPs), effectively interfering with mitogenic signaling pathways. This exerts direct antiproliferative effects on functional and non-functional secretory tumor cells.
- Anti-Angiogenic Potential: Indirectly restricts tumor microenvironment expansion by downregulating the expression and release of vascular endothelial growth factor (VEGF).
Therapeutic Formulation & R&D Applications
Supplied strictly as a raw material for pharmaceutical manufacturing, our Lanreotide API is the critical active component for developing advanced therapies targeting hypersecretory syndromes:
- Long-Acting Depot Formulation Research: Serves as the foundation for the development of innovative delivery systems, including self-assembling supersaturated hydrogels (Autogel architectures) and PLGA microsphere injections designed for 28-day sustained release.
- Endocrinology & Oncology: Core API for the development of generic equivalents targeting Acromegaly management and the symptomatic control of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), specifically carcinoid syndrome.
- Exploratory Clinical Pathways: Utilized as a high-purity reference material for investigating potential indications in refractory ophthalmic pathologies and generalized neuroendocrine disorders.
Technical & Formulation FAQ
Yes. Our Lanreotide API is engineered with highly controlled physicochemical properties, allowing it to spontaneously form stable, supersaturated liquid crystal nanotubes in aqueous environments when subjected to specific preparation protocols. This makes it ideal for developing "Autogel" style deep subcutaneous depot injections.
Our standard commercial API is supplied as Lanreotide Acetate. The acetate salt form provides the optimal balance of solubility and stability required for both microsphere encapsulation and high-concentration aqueous dispersion technologies.
To support strict generic drug development (ANDA submissions), Xi'an Tihealth provides a comprehensive analytical dossier. This includes the Certificate of Analysis (COA), absolute HPLC sequence mapping to confirm the absence of deletion/insertion impurities, Electrospray Ionization Mass Spectrometry (ESI-MS), and rigorous residual solvent tracking.
Xi'an Tihealth Biotechnology Co., Ltd. Statement: Pharmaceutical API intended strictly for laboratory analysis, formulation R&D, and manufacturing. Not for direct clinical administration.
Hot Tags: lanreotide powder cas no.108736-35-2, China lanreotide powder cas no.108736-35-2 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry